11 citations
,
May 2021 in “Journal of Medical Virology” Men are more likely to have severe respiratory viral infections like COVID-19 due to hormonal and genetic differences, while women generally have stronger immune responses.
7 citations
,
May 2022 in “The Journal of Dermatology” Hair loss is a frequent long-term effect of COVID-19, and oral minoxidil is the most common effective treatment.
5 citations
,
May 2022 in “Bionatura” Asthma and high testosterone increase Covid-19 severity, while progesterone protects young women.
3 citations
,
May 2024 in “Frontiers in Physiology” Sex hormone supplements help improve breathing and nerve recovery after spinal injury in rats.
1 citations
,
June 2023 in “International journal of basic science in medicine” Adiantum capillus-veneris may help with respiratory issues, but more research is needed.
December 2024 in “Journal of Investigative Dermatology” People with androgenetic alopecia had milder COVID-19 symptoms during the Omicron wave in China.
April 2021 in “Libyan journal of medical sciences” A woman's hair loss improved with treatment after a COVID-19 infection.
16 citations
,
April 2023 in “Physical Medicine and Rehabilitation Clinics of North America”
Low-level laser therapy may help uninfected cells but has different effects on coronavirus-infected cells.
April 2020 in “BMC endocrine disorders” A woman with childhood growth hormone deficiency had multiple hormone deficiencies and developed serious lung and kidney problems later in life.
35 citations
,
January 2022 in “Clinical Infectious Diseases” Healthcare workers with COVID-19 reported more long-term symptoms, and physical activity may help reduce some of these symptoms.
Finasteride may help reduce COVID-19 infection by altering a key gene.
22 citations
,
October 2021 in “Dermatologic Therapy” COVID-19 may cause temporary hair loss in some people.
16 citations
,
December 2006 in “International Journal of Dermatology” A woman died from cancer that spread from a long-standing cyst on her abdomen.
12 citations
,
March 2004 in “International Journal of Dermatology” A woman with X-linked chronic granulomatous disease developed lupus-like skin lesions, improved with treatment, suggesting a unique skin condition in carriers.
8 citations
,
January 2023 in “Biosensors” Piezoelectric Nanogenerators are promising for non-invasive health monitoring but need efficiency and durability improvements.
5 citations
,
May 2020 in “Dermatologic Therapy” 5-alpha reductase inhibitors might worsen lung recovery in COVID-19 patients, suggesting a pause in their use.
January 2026 in “Biochemical Pharmacology” MitoQ helps protect hair cells from damage in hair loss by boosting a protective enzyme.
June 2023 in “British Journal of Dermatology” Baricitinib was effective and safe for severe hair loss treatment over 6 months.
April 2023 in “Journal of Investigative Dermatology” A protein called MPZL3 in mitochondria slows down hair growth and could be a target for treating hair growth disorders.
Hair keratin treatments can be harmful, potentially causing health issues like skin reactions and cancer.
May 2018 in “Cell stem cell” Myoepithelial cells can repair airways after severe injury.
February 2008 in “Experimental dermatology” Oxidative stress plays a significant role in vitiligo, and both skin and non-skin cells may be involved.
Improve ventilation and address environmental issues to reduce health complaints.
238 citations
,
November 2016 in “Journal of The American Academy of Dermatology” Tofacitinib is effective and safe for severe hair loss, but full regrowth is less likely after 10 years of hair loss.
54 citations
,
September 2019 in “Journal of the European Academy of Dermatology and Venereology” Tofacitinib is somewhat effective for alopecia areata, but more research is needed on its safety and long-term effects.
39 citations
,
January 2019 in “Journal of the American Academy of Dermatology” Tofacitinib may help treat severe childhood alopecia areata, but risks require careful consideration.
20 citations
,
March 2023 in “American Journal of Clinical Dermatology” Baricitinib improved severe hair loss in adults over 52 weeks and was safe to use.
17 citations
,
January 2019 in “Dermatologic Therapy” Tofacitinib is effective and safe for long-term treatment of severe alopecia areata, with many patients achieving complete hair regrowth.
9 citations
,
October 2019 in “Dermatologic Therapy” Oral tofacitinib has a moderate success rate and is generally safe for treating hair loss in some patients.